Allianz SE Has $6.23 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Allianz SE lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 15,352 shares of the medical research company’s stock after selling 470 shares during the quarter. Allianz SE’s holdings in Thermo Fisher Scientific were worth $6,225,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the business. Vanguard Group Inc. increased its stake in Thermo Fisher Scientific by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company’s stock valued at $16,659,627,000 after buying an additional 230,382 shares during the last quarter. Amundi lifted its holdings in Thermo Fisher Scientific by 5.9% during the 1st quarter. Amundi now owns 3,029,044 shares of the medical research company’s stock worth $1,426,316,000 after purchasing an additional 168,197 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Thermo Fisher Scientific by 4.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company’s stock valued at $1,455,774,000 after buying an additional 115,463 shares in the last quarter. Pictet Asset Management Holding SA increased its position in Thermo Fisher Scientific by 7.2% during the 1st quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company’s stock worth $1,432,816,000 after buying an additional 193,378 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Thermo Fisher Scientific by 13.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company’s stock valued at $1,368,859,000 after acquiring an additional 329,974 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In other news, VP Lisa P. Britt sold 10,225 shares of Thermo Fisher Scientific stock in a transaction on Friday, November 7th. The shares were sold at an average price of $571.62, for a total transaction of $5,844,814.50. Following the completion of the sale, the vice president directly owned 14,145 shares of the company’s stock, valued at approximately $8,085,564.90. The trade was a 41.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Joseph R. Holmes sold 385 shares of the company’s stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares of the company’s stock, valued at $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 46,645 shares of company stock valued at $25,825,699. Company insiders own 0.33% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of recent analyst reports. William Blair started coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an “outperform” rating on the stock. Morgan Stanley raised their target price on Thermo Fisher Scientific from $560.00 to $656.00 and gave the company an “overweight” rating in a report on Tuesday, October 28th. Citigroup boosted their price target on Thermo Fisher Scientific from $500.00 to $580.00 and gave the stock a “neutral” rating in a report on Thursday, October 23rd. Cowen reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Thursday, October 23rd. Finally, Raymond James Financial reaffirmed an “outperform” rating and set a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Nineteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $601.65.

Thermo Fisher Scientific Stock Up 0.3%

Shares of NYSE TMO opened at $588.53 on Thursday. The stock has a market capitalization of $221.12 billion, a P/E ratio of 34.00, a P/E/G ratio of 3.27 and a beta of 0.82. The company has a 50-day moving average price of $524.35 and a 200-day moving average price of $465.87. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.50 by $0.29. The company had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.Thermo Fisher Scientific’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period in the prior year, the company posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has approved a share repurchase plan on Thursday, November 6th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to buy up to 2.4% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is 9.94%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.